
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc. has raised the probability of approval for its product RP1 in combination with Opdivo for advanced melanoma to 95%, reflecting strong clinical efficacy evidenced by an objective response rate of approximately 33.6%. The company's ability to scale in-house manufacturing to meet global supply demands contributes positively to its cost of goods sold and overall financial outlook. Furthermore, the initiation of the IGNYTE-3 confirmatory trial with plans to enroll over 100 global sites indicates a robust pipeline and potential for commercial success in the near future.
Bears say
Replimune Group Inc. is facing a negative financial outlook, primarily due to a projected net loss of $2.99 per share for fiscal 2025, which indicates deteriorating financial performance compared to earlier estimates of $2.93 per share. The company is also confronted with significant risks including potential failure to generate effective clinical trial data for its lead candidate, RP1, as well as challenges in obtaining regulatory approval and delivering on its early-stage pipeline. Additionally, concerns regarding possible safety signals and the potential for medium- to long-term dilution create further pressure on Replimune's stock prospects.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares